Smith & Nephew (LON:SN)‘s stock had its “reduce” rating restated by investment analysts at AlphaValue in a note issued to investors on Thursday, Stock Ratings Network reports. They currently have a GBX 701 ($11.25) price target on the stock. AlphaValue’s target price points to a potential downside of 8.31% from the company’s current price.
Smith & Nephew (LON:SN) traded up 0.92% during mid-day trading on Thursday, hitting GBX 771.50. 1,413,142 shares of the company’s stock traded hands. Smith & Nephew has a one year low of GBX 636.00 and a one year high of GBX 805.50. The stock has a 50-day moving average of GBX 778.4 and a 200-day moving average of GBX 761.5. The company’s market cap is £6.982 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew in a research note to investors on Tuesday. They now have a GBX 740 ($11.87) price target on the stock. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew in a research note to investors on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 759.24 ($12.18).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.